Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Piceatannol 3'-O-glucoside in preparation of product for treating and/or preventing non-alcoholic fatty liver disease

A non-alcoholic technology of trizaperoside, which is applied in the field of application of trizaperoside in the preparation of products for the treatment and/or prevention of non-alcoholic fatty liver disease, can solve the problems of no treatment and prevention of NAFLD, and achieve a good market Prospect, improvement of hepatocyte steatosis, effect of improving cultured hepatocyte steatosis

Pending Publication Date: 2020-04-14
KPC PHARM INC
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The existing technology shows that trizaperine has the activity of treating ischemic cardiovascular and cerebrovascular diseases, but there is no report that it can be used for the treatment and prevention of NAFLD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Piceatannol 3'-O-glucoside in preparation of product for treating and/or preventing non-alcoholic fatty liver disease
  • Application of Piceatannol 3'-O-glucoside in preparation of product for treating and/or preventing non-alcoholic fatty liver disease
  • Application of Piceatannol 3'-O-glucoside in preparation of product for treating and/or preventing non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1: Discussion on the protective effect of tristilbene glycosides on non-alcoholic liver cell injury

[0037] 1 Experimental materials

[0038] 1.1 Test product

[0039] Tristilbene, molecular weight 406, white crystal or crystalline powder, purity 99.6%, batch number 20120402;

[0040] 1.2 Experimental animals

[0041] Select 44 healthy male C57BL / 6 mice, weighing 19-23g, all purchased from Hunan Slack Jingda Experimental Animal Co., Ltd., experimental animal production license number: SCXK (Xiang) 2016-0002, and bred in Kunming Pharmaceutical Group Research Institute, group breeding in PVC transparent plastic boxes, each box ≤ 6, fed with the corresponding feed every day, free drinking water, and changing cages and bedding materials according to the situation. Temperature 20-25°C (daily temperature difference ≤3°C), humidity 40%-70%, lighting 12h: 12h alternating light and dark, illumination 150-300lx, noise ≤60dB, experimental animal use license: SYCK (Dian...

Embodiment 2

[0086] The tablet of this example consists of the following components: 10 g of tristilbene glycosides, 20 g of microcrystalline cellulose, 20 g of pregelatinized starch, 20 g of cross-linked polyvinylpyrrolidone, and 1 g of micropowdered silica gel.

[0087] The above-mentioned raw materials were mixed, and trizaperine tablets were prepared according to conventional methods.

Embodiment 3

[0089] The capsule of this embodiment is composed of the following components: 10 g of stilbene glycosides, 30 g of microcrystalline cellulose, 5 g of lactose, an appropriate amount of povidone K-30, and 1 g of magnesium stearate.

[0090] Mix the above-mentioned raw materials, and prepare tristilbene capsules according to conventional methods.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological pharmacy, and discloses application of Piceatannol 3'-O-glucoside in preparation of a product for treating and / or preventing non-alcoholic fatty liver disease. Researches show that after the Piceatannol 3'-O-glucoside is continuously administrated to a non-alcoholic fatty liver disease (NAFLD) model mouse for four weeks, the contents of TC, TG and LDL in serum are remarkably reduced and the content of HDL is remarkably increased, which shows that the medicine has a lipid regulating effect; activity of AST and ALT in serum is remarkablyweakened and infiltration of inflammatory factors in liver tissue is relieved, which shows that the medicine has a liver protection effect; the fat content of the liver can be reduced and the pathological form of the fatty liver can be improved, which indicates that the medicine has an antagonistic effect on NASH. The test result shows that the Piceatannol 3'-O-glucoside has good development andapplication value in the aspect of preventing and treating the non-alcoholic fatty liver disease.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of trizaperone in the preparation of products for the treatment and / or prevention of non-alcoholic fatty liver disease. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) refers to liver metabolic diseases caused by long-term heavy drinking and other clear liver damage factors, and the accumulation of lipids mainly in triglycerides in liver cells is a pathological change. In patients with NAFLD, liver fat metabolism is impaired, causing a large amount of fatty substances to accumulate in liver cells (simple fatty liver), which in turn leads to fatty degeneration of liver cells, liver cell damage, inflammatory response, and liver fibrosis (nonalcoholic steatohepatitis). , NASH). Simple fatty liver is a relatively benign stage of NAFLD and can be easily reversed. 10%-20% of simple fatty liver can progress to NASH. At present, NAS...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7034A61P1/16A61P3/06A23L33/105
CPCA61K31/7034A61P1/16A61P3/06A23L33/105A23V2002/00A23V2200/30A23V2200/3262A23V2250/21A23V2250/51084A23V2250/5118A23V2250/612A23V2250/6418A23V2250/5086A23V2250/246A61K9/2054A61K9/4866A61K9/1623A61K9/0056A61K9/2031Y02A50/30A61K9/1617A61K9/1652A61K9/2009A61K9/2027A61K9/2059A61K9/4858
Inventor 刘一丹刘军锋杨旭娟黄茜黄青孟珂刘国光尚建华
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com